Anthony Fraudci co-authored a new scientific study calling for “next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses.”
The study, which came out January in Cell Host & Microbe, talked about the “deficiencies” of current ‘vaccines’ for these pathogens.
The paper begins by discussing the downfalls of influenza vaccines.
From Cell Host & Microbe:
Although current influenza vaccines reduce the risk of severe disease, hospitalization, and death to some degree, their effectiveness against clinically apparent infection is decidedly suboptimal, ranging from 14% to 60% over the past 15 influenza seasons. Furthermore, the duration of vaccine-elicited immunity is measured only in months. Current vaccines require annual re-vaccination with updated formulations that are frequently not precisely matched to circulating virus strains. Although annual influenza vaccinations are strongly recommended for most of the general public and especially for persons in high-risk groups, including the elderly, those with chronic diseases, and pregnant women, vaccine acceptance by the general public is not ideal.
As of 2022, after more than 60 years of experience with influenza vaccines, very little improvement in vaccine prevention of infection has been noted. As pointed out decades ago, and still true today, the rates of effectiveness of our best approved influenza vaccines would be inadequate for licensure for most other vaccine-preventable diseases.
The paper continued by discussing the “deficiencies” of the COVID-19 shots.
“However, as variant SARS-CoV-2 strains have emerged, deficiencies in these vaccines reminiscent of influenza vaccines have become apparent,” the paper states.
The authors continue to explain how SARS-CoV-2 ‘vaccines’ provide insufficient protection against COVID-19.
Dr. Fauci Calls for Next-Generation Vaccines for Respiratory Viruses
“It is not surprising that none of the predominantly mucosal respiratory viruses have ever been effectively controlled by vaccines.”https://t.co/gkP0ToemAd pic.twitter.com/fih1Z1RFxW
— Chief Nerd (@TheChiefNerd) February 7, 2023
Cont. from Cell Host & Microbe:
During the COVID-19 pandemic, the rapid development and deployment of SARS-CoV-2 vaccines has saved innumerable lives and helped to achieve early partial pandemic control. However, as variant SARS-CoV-2 strains have emerged, deficiencies in these vaccines reminiscent of influenza vaccines have become apparent. The vaccines for these two very different viruses have common characteristics: they elicit incomplete and short-lived protection against evolving virus variants that escape population immunity. Considering that vaccine development and licensure is a long and complex process requiring years of preclinical and clinical safety and efficacy data, the limitations of influenza and SARS-CoV-2 vaccines remind us that candidate vaccines for most other respiratory viruses have to date been insufficiently protective for consideration of licensure
🚨BREAKING — Dr. Fauci Publishes An Article Admitting Current COVID-19 Vaccines Cannot Effectively Control SARS-CoV-2 Because It Rapidly Replicates On Top Layer Respiratory Mucosal Tissueshttps://t.co/GsoOMx47Ve pic.twitter.com/kh3Xa2Kw00
— James Cintolo, RN FN CPT (@healthbyjames) February 6, 2023
In another section, the authors explain the challenges of developing ‘vaccines’ for “respiratory viruses such as influenza viruses, SARS-CoV-2, and RSV.”
Cont. from Cell Host & Microbe:
In stark contrast, the non-systemic respiratory viruses such as influenza viruses, SARS-CoV-2, and RSV tend to have significantly shorter incubation periods (Table 1) and rapid courses of viral replication. They replicate predominantly in local mucosal tissue, without causing viremia, and do not significantly encounter the systemic immune system or the full force of adaptive immune responses, which take at least 5–7 days to mature, usually well after the peak of viral replication and onward transmission to others. SARS-CoV-2 “RNAemia” (circulation of viral RNA in the bloodstream, as is seen with most mucosal respiratory virus infections, as distinct from viremia, in which infectious viruses can be cultured from the blood), has been reported, and RT-PCR levels of viral RNA have been linked to severe disease, similar to studies of influenza RNAemia. As a result, the non-systemically replicating respiratory viruses, apparently including SARS-CoV-2, tend to repeatedly re-infect people over their lifetimes without ever eliciting complete and durable protection.Another important factor to consider is that although RNA viruses share a similar inherent RNA-dependent RNA polymerase error rate, different viruses (and different open reading frames within their genomes) differ in their tolerance for mutation. Mutational constraints can be related to frequent overlapping open reading frames or functional constraints on the acquisition of nonsynonymous mutations as is the case, for example, with measles virus. In contrast, the external influenza A virus hemagglutinin and neuraminidase proteins are comparatively plastic, and positively selected nonsynonymous mutations result in immunologically significant antigenic drift, by the acquisition of nonsynonymous mutations in antigenic epitopes, as well as by altering the N-linked glycosylation patterns. Rapid antigenic drift affects the control of annual influenza epidemics and complicates the effort to produce broadly protective, “universal” influenza vaccines. The SARS-CoV-2 spike protein has shown a similar plasticity, with the emergence of multiple variants with altered antigenicity that has complicated its control through current vaccination strategies.Although rapid evolution of antigenically variable mucosal viruses like influenza A viruses and SARS-CoV-2 complicate next-generation vaccine design, other mucosal-only respiratory viruses, such as RSV, have shown much less antigenic plasticity; however, it still causes repeated infections over a lifetime without the development of long-term protective immunity. Thus, although genetic and antigenic variability of viruses like influenza and SARS-CoV-2 make vaccine design more challenging, these factors by themselves cannot fully explain the lack of elicitation of long-term protective immunity against other respiratory mucosal viruses like the more phenotypically stable RSV.Taking all of these factors into account, it is not surprising that none of the predominantly mucosal respiratory viruses have ever been effectively controlled by vaccines. This observation raises a question of fundamental importance: if natural mucosal respiratory virus infections do not elicit complete and long-term protective immunity against reinfection, how can we expect vaccines, especially systemically administered non-replicating vaccines, to do so? This is a major challenge for future vaccine development, and overcoming it is critical as we work to develop “next-generation” vaccines.
Fauci explained in the study cited above why a vaccine-induced blood (humoral) response to Sars-Cov-2 would never stop respiratory infections. And yet, he lied to us for THREE YEARS about how vaccines would be the key to “getting out of the pandemic” and getting to herd immunity.
Yet, Fraudci said the experimental injections would help us achieve ‘herd immunity.’
Igor Chudov shared the following clip:
Fauci: with a vaccine 95% effective, we can get to herd immunity in 2021. pic.twitter.com/UmrcCwiWFB
— Igor Chudov 🐭 (@ichudov) February 6, 2023
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!